Medication for Women with Advanced Breast Cancer

IMAGE All women with advanced breast cancer face a difficult and uncertain future. Most of them endure long courses of treatment that leave them looking to alternative or experimental therapies for a cure. A drug called trastuzumab (Herceptin) attacks a particularly aggressive form of breast cancer in a novel way. One aggressive form of breast cancer is characterized by an overabundance of a protein known as human epithelial growth factor receptor-2 (HER2). This protein stimulates the growth of breast tumors. Trastuzumab is a monoclonal antibody, which blocks the HER2 receptor. This inhibits the growth of cancer cells. Scientists have known since the 1980's that women whose breast cancers produce too much HER2 have cancers that are more aggressive and more likely to metastasize, or spread. Trastuzumab can enhance the effectiveness of standard chemotherapy treatments by targeting the HER2 receptor and inhibiting its activity.

Trastuzumab May Delay Cancer Progression

Several clinical studies show that women with HER2-positive tumors using trastuzumab with chemotherapy have slower cancer growth and better response to treatment. An early study from 2001 showed that trastuzumab when added to chemotherapy was effective in slowing disease progression in HER2-positive breast cancer patients. In women with HER2-positive operable breast cancer, trastuzumab combined with chemotherapy improved survival outcome compared to those without trastuzumab. Combined results of two studies involving over 3,300 women found longer survival rates after 1 year of treatment with trastuzumab added to chemotherapy compared to those without trastuzumab. In another study (the HERA trial), 1 year of treatment resulted in significant survival and less disease progression. In follow-up studies at 2 and 4 years, disease-free survival was maintained. Women who began treatment with trastuzumab after the first year of the study had similar results. There was little difference however, in overall survival or risk of death at the 4 year follow-up. Unfortunately, although trastuzumab may be able to slow the growth of cancer cells, it is also associated with some serious side effects.

leave comments
0
Did you like this? Share with your family and friends.
Related Topics: Health And Healing
Meet Our Health Experts
beginners heart

Beginner's Heart

Britton Gildersleeve
New! wanted the perfect house to become a home
Simply Fabulous

Simply Fabulous

Jennifer Baxter
God the Ultimate Search Engine

Mindfulness Matters

Arnie Kozak
Everything Essential Buddhism Book


Advertisement

Our Free Newsletter
click here to see all of our uplifting newsletters »

 

Advertisement

DiggDeliciousNewsvineRedditStumbleTechnoratiFacebook